Table 1 |
|||
| Baseline demographics, overview of antibiotic courses, outcome variables | |||
| Phase I (91 days) | Phase II (110 days) | p-value | |
| Admissions | 174 | 185 | 0.48 |
| Hospitalisation days | 952 | 1186 | 0.84 |
| Hospitalisation days / admissiona | 5.47 (1/3/41) | 6.41 (1/3/71) | 0.24 |
| Fatal casualities | 0 | 3 | 0.25 |
| Infection-related fatal casualities | 0 | 0 | 1 |
| Sex (% male) | 58% | 60.5% | 0.23 |
| Age at admissionb | 6 mt (0–16 yrs) | 7 mt (0–16 yrs) | 0.48 |
| Cardiosurgery admissions | 67.8% | 57.8% | 0.05 |
| Cardiology admissions | 13.2% | 20.5% | 0.06 |
| Respiratory admissions | 10.3% | 13.5% | 0.35 |
| Other admissionsc | 8.6% | 8.1% | 0.86 |
| Antibiotic courses total | 194 | 182 | 0.14 |
| Prophylaxis courses | 66.5% | 55.5% | 0.02* |
| Non-proven infection courses | 27.3% | 31.3% | 0.39 |
| Proven infection courses | 6.2% | 13.2% | 0.02* |
| Secondary antibiotic courses total | 8.2% | 6% | 0.59 |
| Secondary courses for prophylaxis | 2.1% | 1.1% | 0.68 |
| Secondary courses for non-proven infection | 4.1% | 4.4% | 0.90 |
| Secondary courses for proven infection | 2.1% | 0.5% | 0.37 |
| Infection relapse rate (non-proven + proven) | 6.2% | 5.0% | 0.62 |
Baseline demographics. *statistically significant, amean (min/median/max), bmedian (min-max), cgeneral paediatric surgery, ENT, thoracic surgery.
Stocker et al. BMC Pediatrics 2012 12:196 doi:10.1186/1471-2431-12-196
